Related Experiment Videos
Positional candidate gene cloning of CLN1
1Department of Internal Medicine and the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas 75390, USA. hofmann@simmons.swmed.edu
Advances in Genetics
|May 3, 2001
Summary
Mutations in the CLN1 gene cause infantile neuronal ceroid lipofuscinosis (INCL). Recombinant palmitoyl-protein thioesterase (PPT) can reverse substrate accumulation, offering hope for new INCL therapies.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Infantile neuronal ceroid lipofuscinosis (INCL) is a severe neurodegenerative disorder.
- It is caused by mutations in the CLN1 gene, which encodes palmitoyl-protein thioesterase (PPT).
- PPT is a lysosomal enzyme crucial for protein deacylation.
Purpose of the Study:
- To identify the gene responsible for INCL.
- To understand the function of PPT in cellular processes.
- To explore potential therapeutic strategies for INCL.
Main Methods:
- Gene mapping to identify the CLN1 critical region.
- Mutation analysis in PPT in affected families.
- Cellular studies to assess the effect of recombinant PPT.
- Histological examination of patient tissues.
Main Results:
- The CLN1 gene, encoding PPT, was conclusively identified as the disease gene for INCL.
- PPT deficiency leads to the accumulation of fatty acyl cysteine thioesters.
- Recombinant PPT administration reversed substrate accumulation in INCL cells via mannose 6-phosphate receptor pathway.
- Over two dozen PPT mutations identified globally; some missense mutations cause later onset due to residual activity.
Conclusions:
- INCL is caused by a defect in the soluble lysosomal enzyme PPT.
- Therapeutic approaches including enzyme replacement, stem cell transplantation, gene therapy, and metabolic therapy are promising.
- Understanding PPT's enzymatic function opens avenues for targeted INCL treatments.